Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

8.25
+0.03000.37%
Volume:102.44K
Turnover:836.02K
Market Cap:1.13B
PE:-2.15
High:8.31
Open:8.06
Low:8.05
Close:8.22
Loading ...

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Business Wire
·
08 Jan

Vir Biotechnology price target lowered to $14 from $15 at BofA

TipRanks
·
08 Jan

BofA Securities Trims Price Target on Vir Biotechnology to $14 From $15, Maintains Neutral Rating

MT Newswires Live
·
08 Jan

US FDA revokes authorization for four COVID antibody drugs

Reuters
·
24 Dec 2024

US FDA revokes authorization for five COVID treatments

Reuters
·
24 Dec 2024

BRIEF-US FDA Revoked Emergency Use Authorization For Certain COVID Drugs As Of Dec 13

Reuters
·
24 Dec 2024

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire
·
18 Dec 2024

Vir Biotechnology's Tobevibart, Elebsiran Receive US, EU Designations for Hepatitis Delta Treatment

MT Newswires Live
·
13 Dec 2024

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and Ema Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

THOMSON REUTERS
·
13 Dec 2024

Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025

THOMSON REUTERS
·
13 Dec 2024

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Business Wire
·
13 Dec 2024

JANX Stock Hits Record High on Prostate Cancer Study Data

Zacks
·
04 Dec 2024

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results -- Barrons.com

Dow Jones
·
03 Dec 2024

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)

TIPRANKS
·
03 Dec 2024

Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?

Simply Wall St.
·
01 Dec 2024

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Business Wire
·
26 Nov 2024